ProCE Banner Activity

SELECT Pooled Analysis: Incidence and Risk Factors for VTE in Patients With RA Treated With Upadacitinib

Slideset Download
Conference Coverage
Pooled analysis of 5 phase III trials in RA suggests that history of VTE and higher BMI were risk factors for VTE in those receiving upadacitinib.

Released: November 09, 2020

Expiration: November 08, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp